{"id":93706,"date":"2026-05-21T16:27:04","date_gmt":"2026-05-21T10:57:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=93706"},"modified":"2026-05-21T16:27:05","modified_gmt":"2026-05-21T10:57:05","slug":"gufic-biosciences-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/","title":{"rendered":"Gufic Biosciences Analyst Review May 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/guficbio\/gufic-biosciences-ltd-share-price-today\">Gufic Biosciences<\/a> analyst review<\/strong> for May 2026 covers the key data investors need for GUFICBIO at its current price of Rs 395. Gufic Biosciences (NSE: GUFICBIO) is a specialty pharmaceutical company with a market capitalisation of approximately Rs 2,200 crore, focusing on lyophilised injectables and critical care products. The analyst consensus target of Rs 480 implies meaningful upside, and this <strong>Gufic Biosciences analyst review<\/strong> examines technical levels, business performance, valuation, and key risks for GUFICBIO through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Gufic_Biosciences_Company_Snapshot_May_2026\" title=\"Gufic Biosciences Company Snapshot May 2026\">Gufic Biosciences Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Analyst_Insight_in_This_Gufic_Biosciences_Analyst_Review\" title=\"Analyst Insight in This Gufic Biosciences Analyst Review\">Analyst Insight in This Gufic Biosciences Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Technical_Analysis_in_This_Gufic_Biosciences_Analyst_Review\" title=\"Technical Analysis in This Gufic Biosciences Analyst Review\">Technical Analysis in This Gufic Biosciences Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Lyophilised_Injectable_Manufacturing_Core_Technology\" title=\"Lyophilised Injectable Manufacturing (Core Technology)\">Lyophilised Injectable Manufacturing (Core Technology)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Critical_Care_Antifungal_and_Anti-infective_Drugs\" title=\"Critical Care Antifungal and Anti-infective Drugs\">Critical Care Antifungal and Anti-infective Drugs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Hospital_and_Institutional_Sales_Channel\" title=\"Hospital and Institutional Sales Channel\">Hospital and Institutional Sales Channel<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Valuation_in_This_Gufic_Biosciences_Analyst_Review\" title=\"Valuation in This Gufic Biosciences Analyst Review\">Valuation in This Gufic Biosciences Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Trade_Outlook_for_Gufic_Biosciences\" title=\"Trade Outlook for Gufic Biosciences\">Trade Outlook for Gufic Biosciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Key_Risks_for_Gufic_Biosciences_in_FY27\" title=\"Key Risks for Gufic Biosciences in FY27\">Key Risks for Gufic Biosciences in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Conclusion_Gufic_Biosciences_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Gufic Biosciences Analyst Review Verdict for 2026\">Conclusion: Gufic Biosciences Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Frequently_Asked_Questions_Gufic_Biosciences_Analyst_Review_2026\" title=\"Frequently Asked Questions: Gufic Biosciences Analyst Review 2026\">Frequently Asked Questions: Gufic Biosciences Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#What_is_the_analyst_target_for_Gufic_Biosciences_in_2026\" title=\"What is the analyst target for Gufic Biosciences in 2026?\">What is the analyst target for Gufic Biosciences in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Is_Gufic_Biosciences_a_good_investment_at_Rs_395\" title=\"Is Gufic Biosciences a good investment at Rs 395?\">Is Gufic Biosciences a good investment at Rs 395?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#What_is_Gufic_Biosciencess_52-week_high_and_low\" title=\"What is Gufic Biosciences&#8217;s 52-week high and low?\">What is Gufic Biosciences&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#What_are_the_key_risks_for_Gufic_Biosciences\" title=\"What are the key risks for Gufic Biosciences?\">What are the key risks for Gufic Biosciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/gufic-biosciences-analyst-review-2026\/#Where_can_I_track_live_data_for_Gufic_Biosciences\" title=\"Where can I track live data for Gufic Biosciences?\">Where can I track live data for Gufic Biosciences?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Gufic_Biosciences_Company_Snapshot_May_2026\"><\/span><strong>Gufic Biosciences Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gufic Biosciences&#8217; lyophilised injectable manufacturing capability (complex freeze-dried drugs) is rare and high-barrier. Critical care products (antifungals, anti-infectives) sold in hospitals across India generate recurring institutional revenue. The table below summarises the key data referenced in this <strong>Gufic Biosciences analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>GUFICBIO<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals &#8211; Injectables and Lyophilisation<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 395<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 540<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 340<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 2,200 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>30x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 480<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 580<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 320<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Gufic_Biosciences_Analyst_Review\"><\/span><strong>Analyst Insight in This Gufic Biosciences Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Senior Research Analyst <strong>Ankit Jaiswal<\/strong> flags Gufic Biosciences as a stock to watch in May 2026. At Rs 395, Ankit Jaiswal identifies key support in the Rs 347 to Rs 375 band and resistance near Rs 419. He suggests watching Gufic Biosciences for a potential move toward Rs 480, subject to Pharmaceuticals &#8211; Injectables and Lyophilisation sector momentum and Nifty 50 direction. Ankit Jaiswal&#8217;s view is one input in this <strong>Gufic Biosciences analyst review<\/strong> and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Gufic_Biosciences_Analyst_Review\"><\/span><strong>Technical Analysis in This Gufic Biosciences Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 395, GUFICBIO is trading within its 52-week band of Rs 340 to Rs 540. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 347 to Rs 375 band while resistance is seen in the Rs 419 to Rs 438 zone. A sustained move above Rs 419 could open the path toward the analyst consensus target of Rs 480 as identified in this <strong>Gufic Biosciences analyst review<\/strong>.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 347 to Rs 375 &#8211; investors tracking this <strong>Gufic Biosciences analyst review<\/strong> should watch for stabilisation or a bounce in this range as a potential accumulation signal for GUFICBIO.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 419 to Rs 438 &#8211; a sustained close above Rs 419 would be a positive breakout signal worth flagging in this <strong>Gufic Biosciences analyst review<\/strong>.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 480 represents the base-case upside scenario in this <strong>Gufic Biosciences analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Lyophilised_Injectable_Manufacturing_Core_Technology\"><\/span><strong>Lyophilised Injectable Manufacturing (Core Technology)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Gufic Biosciences, directly supporting the earnings trajectory toward the consensus target of Rs 480.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Critical_Care_Antifungal_and_Anti-infective_Drugs\"><\/span><strong>Critical Care Antifungal and Anti-infective Drugs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Gufic Biosciences&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Hospital_and_Institutional_Sales_Channel\"><\/span><strong>Hospital and Institutional Sales Channel<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Gufic Biosciences and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Gufic_Biosciences_Analyst_Review\"><\/span><strong>Valuation in This Gufic Biosciences Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 395, Gufic Biosciences trades at a trailing P\/E of 30x. This <strong>Gufic Biosciences analyst review<\/strong> presents three scenarios: a bull case of Rs 580 on strong earnings delivery, a base case of Rs 480 at analyst consensus, and a bear case of Rs 320 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this <strong>Gufic Biosciences analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 580<\/td>\n<td>Strong earnings delivery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 480<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 320<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Gufic_Biosciences\"><\/span><strong>Trade Outlook for Gufic Biosciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Gufic Biosciences analyst review<\/strong>, investors might watch GUFICBIO near the support zone of Rs 347 to Rs 375 for potential opportunities. A flag above Rs 419 could suggest improving momentum toward Rs 480. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Gufic_Biosciences_in_FY27\"><\/span><strong>Key Risks for Gufic Biosciences in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Gufic Biosciences analyst review<\/strong> must assess downside risks. Key risks for Gufic Biosciences include a macro slowdown affecting Pharmaceuticals &#8211; Injectables and Lyophilisation sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in GUFICBIO.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Gufic_Biosciences_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Gufic Biosciences Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Gufic Biosciences analyst review<\/strong> concludes that at Rs 395, GUFICBIO offers a defined risk-reward with a consensus target of Rs 480. The 52-week range of Rs 340 to Rs 540 provides context on the current entry point. Use this <strong>Gufic Biosciences analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on GUFICBIO.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Gufic_Biosciences_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Gufic Biosciences Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Gufic_Biosciences_in_2026\"><\/span><strong>What is the analyst target for Gufic Biosciences in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 480, with a bull case of Rs 580 and a bear case of Rs 320. This <strong>Gufic Biosciences analyst review<\/strong> recommends monitoring Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Gufic_Biosciences_a_good_investment_at_Rs_395\"><\/span><strong>Is Gufic Biosciences a good investment at Rs 395?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 395 with a P\/E of 30x and a consensus target of Rs 480, this <strong>Gufic Biosciences analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals &#8211; Injectables and Lyophilisation sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Gufic_Biosciencess_52-week_high_and_low\"><\/span><strong>What is Gufic Biosciences&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 540 and the 52-week low is Rs 340. At Rs 395, GUFICBIO is positioned within this range as noted in this <strong>Gufic Biosciences analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Gufic_Biosciences\"><\/span><strong>What are the key risks for Gufic Biosciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals &#8211; Injectables and Lyophilisation sector as assessed in this <strong>Gufic Biosciences analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_live_data_for_Gufic_Biosciences\"><\/span><strong>Where can I track live data for Gufic Biosciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Gufic Biosciences&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this <strong>Gufic Biosciences analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gufic Biosciences analyst review 2026: CMP Rs 395, MCap Rs 2,200 Cr, PE 30x. Pharmaceuticals &#8211; Injectables and Lyophilisation sector outlook and technical level<\/p>\n","protected":false},"author":26,"featured_media":94251,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-93706","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779361047:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_focus_keyword":["Gufic Biosciences Analyst Review"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Gufic Biosciences Analyst Review 2026: Key Levels and Outlook"],"rank_math_description":["Gufic Biosciences analyst review 2026: CMP Rs 395, MCap Rs 2,200 Cr, PE 30x. Pharmaceuticals - Injectables and Lyophilisation sector outlook and technical level"],"_thumbnail_id":["94251"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12822"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/21162644\/Gufic-Biosciences-Analyst-Review-May-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=93706"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93706\/revisions"}],"predecessor-version":[{"id":94253,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93706\/revisions\/94253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/94251"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=93706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=93706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=93706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}